
Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. (CGEM)
WebsitePrice
Market cap
Next catalystDec 13, 2026CLN-049 — Phase 1 AML/MDS dose escalation · Phase 1 dataCompany release ↗
Cash
Chart & Events
Core Clinical
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Clinical
Upcoming clinical milestones
Other pipelines
Partner / License out
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved